AbbVie announces Viekira Pak sales reach nearly $400 million

AbbVie announced second quarter financial results and showed Viekira Pak global sales were nearly $400 million, which assisted the company in reaching an overall global sales total of $5 billion, according to a press release from AbbVie.

According to the financial report, global sales were $5.475 billion for the second quarter, which is an 11% increase from the second quarter of 2014. The release states that the total company sales growth was “driven” by Viekira Pak (ombitasvir/paritaprevir/ritonavir plus dasabuvir, AbbVie) sales, which are currently approved for the treatment of HCV in 47 countries. In the U.S., Viekira Pak earned $227 million in sales and $158 million internationally.

Overall revenues were approximately $3.4 billion in the U.S. and $2.1 billion internationally, according to the release.

In addition to Viekira Pak, global Humira (adalimumab) sales also increased 16.4% on an operational basis, or 7.6% taking the impact of foreign exchange rate fluctuations into consideration. The release stated that the growth of Humira in the U.S. was driven by double-digit growth across rheumatology, dermatology and gastroenterology, the three major market categories. However, Humira international sales decreased by almost 18% in the second quarter due to unfavorable foreign exchange.

Other drugs that experienced significant growth for the quarter were Creon (pancrelipase), Synthroid (levothyroxine sodium) and Duodopa. 

“We are pleased with the high level of performance we've delivered through the first-half of 2015, consistent with our commitment to shareholders for top-tier growth this year and beyond,” Richard A. Gonzalez, chairman and CEO of AbbVie, said in the release. “With the completion of the Pharmacyclics transaction, continued momentum from our on-market products and rapid evolution of our robust development pipeline, we are well positioned to deliver strong performance in the future.”

In addition to financial results, AbbVie reported products and their pipeline highlighted during the second quarter of 2015. These items include: the acquisition of Pharmacyclics; FDA granting priority review for its investigational, interferon-free therapy for the treatment of chronic HCV genotype 4 in the U.S.; the FDA granting Viekira Pak orphan drug designation for the treatment of HCV infection in pediatric patients between ages 0 and 16 years; among other research, according to the release.

Disclosures: Gonzalez reports being employed by AbbVie.

AbbVie announced second quarter financial results and showed Viekira Pak global sales were nearly $400 million, which assisted the company in reaching an overall global sales total of $5 billion, according to a press release from AbbVie.

According to the financial report, global sales were $5.475 billion for the second quarter, which is an 11% increase from the second quarter of 2014. The release states that the total company sales growth was “driven” by Viekira Pak (ombitasvir/paritaprevir/ritonavir plus dasabuvir, AbbVie) sales, which are currently approved for the treatment of HCV in 47 countries. In the U.S., Viekira Pak earned $227 million in sales and $158 million internationally.

Overall revenues were approximately $3.4 billion in the U.S. and $2.1 billion internationally, according to the release.

In addition to Viekira Pak, global Humira (adalimumab) sales also increased 16.4% on an operational basis, or 7.6% taking the impact of foreign exchange rate fluctuations into consideration. The release stated that the growth of Humira in the U.S. was driven by double-digit growth across rheumatology, dermatology and gastroenterology, the three major market categories. However, Humira international sales decreased by almost 18% in the second quarter due to unfavorable foreign exchange.

Other drugs that experienced significant growth for the quarter were Creon (pancrelipase), Synthroid (levothyroxine sodium) and Duodopa. 

“We are pleased with the high level of performance we've delivered through the first-half of 2015, consistent with our commitment to shareholders for top-tier growth this year and beyond,” Richard A. Gonzalez, chairman and CEO of AbbVie, said in the release. “With the completion of the Pharmacyclics transaction, continued momentum from our on-market products and rapid evolution of our robust development pipeline, we are well positioned to deliver strong performance in the future.”

In addition to financial results, AbbVie reported products and their pipeline highlighted during the second quarter of 2015. These items include: the acquisition of Pharmacyclics; FDA granting priority review for its investigational, interferon-free therapy for the treatment of chronic HCV genotype 4 in the U.S.; the FDA granting Viekira Pak orphan drug designation for the treatment of HCV infection in pediatric patients between ages 0 and 16 years; among other research, according to the release.

Disclosures: Gonzalez reports being employed by AbbVie.